contact us

Use the form on the right to contact us.

You can edit the text in this area, and change where the contact form on the right submits to, by entering edit mode using the modes on the bottom right.


123 Street Avenue, City Town, 99999

(123) 555-6789


You can set your address, phone number, email and site description in the settings tab.
Link to read me page with more information.


Filtering by Tag: Annie Wilkinson

Needs of the poorest must be central to tackling antibiotic resistance

Future Health Systems

Launched this week is a major report on tackling the growing resistance to antibiotics by the UK Government and the Wellcome Trust. The authors of this blog post fully support its call for the G20 and the UN to take the lead in building a global coalition for action to address this urgent issue, and urge world leaders to consider the unmet needs of the poorest as central to a solution. 

As the World Health Assembly and the G7 Summit meet next week, their recommendations must recognise that very large numbers of people still do not have access to antibiotic treatment when they have an infection. Action on antibiotic resistance should not undermine the continuing need to ensure everyone has access to the medicines they require to live full and healthy lives - a goal which has not yet been consistently reached outside of richer countries. 

Read More

Capturing the legacy of and learning from long-term programmes using innovation histories

Future Health Systems

At the recent workshop on methods for complex adaptive systems (CAS) research in Baltimore, jointly organised by the STEPS Centre and Future Health Systems, thoughts turned to the legacy of such long-term programmes. Though they had different funders, both STEPS and FHS started in 2006. So now, as both programmes start thinking about their 10th anniversaries, how can we begin to summarise all that research and the influence that it has had?

Read More

The ethical implications of new diagnostic technologies: how personal should we get?

Future Health Systems

Diagnostic categories will always be a site of contestation, often linked as much to contemporary standards of morality and normality as to medicine’s capacity to detect disease. But with the global diagnostic industry expanding to be worth $49.2 billion in 2012, and with emerging NCD markets in the BRIC countries behind much of that growth, it is timely to ask if there are developments in diagnostics that are bringing new social, moral or legal concerns to the fore. And how might these play out in the emerging markets?

Read More